Michael Loughner, MD
Endocrinology, Diabetes & Metabolism · Denver, CONPI 1639216906
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by AbbVie at 36.8% of the total. Reporting peaked in 2019 at $14,364 and has fallen 84.0% since, to $2,302 in 2025.
Across 1,067 payments — averaging $30.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- AstraZeneca$6K
- Antares Pharma, Inc.$2K
- Amneal Pharmaceuticals LLC$2K
- Amgen$1K
- Novo Nordisk$1K
- plus $8K from 47 others
What the payments were for
- Speaking & faculty fees$15,20047%
- Travel & lodging$1180%
- Food & beverage$16,90352%
- Education$660%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$7,482
- FARXIGA$4,927
- XYOSTED$128
- Prolia$121
- CeQur Simplicity$117
How this compares
$32,346 in reported general payments places this provider in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $230,139 |
| MounjaroTirzepatide | 106 | $178,334 |
| JardianceEmpagliflozin | 97 | $168,417 |
| TrulicityDulaglutide | 55 | $89,809 |
| FarxigaDapagliflozin Propanediol | 82 | $79,198 |
| SynthroidLevothyroxine Sodium | 590 | $62,172 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $57,859 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $26,223 |
| JanuviaSitagliptin Phosphate | 26 | $24,377 |
| LyumjevInsulin Lispro-Aabc | 11 | $22,894 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $22,043 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 99 | $15,820 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $15,499 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $15,035 |
| XyostedTestosterone Enanthate | 13 | $12,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $1,189 | $294,344185 claims |
| Novo NordiskOzempic, Novolog | $1,366 | $234,226142 claims |
| Boehringer IngelheimJardiance | $256 | $168,41797 claims |
| AstraZenecaFarxiga | $6,125 | $79,19882 claims |
| AbbVieSynthroid, Armour Thyroid | $11,901 | $63,752611 claims |
| MerckJanuvia | $161 | $24,37726 claims |
| Antares Pharma, Inc.Xyosted | $2,300 | $12,34913 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $1,528 | $8,677432 claims |
| IBSA Pharma Inc.Tirosint | $473 | $4,33311 claims |
| Sanofi-aventis U.S. LLCLantus | $1,053 | $3,74914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Denver
- Daniel BessesenDenver$34K
- Leonard ZemelDenver$19K
- Alex GoldsmithDenver$12K
- Daniel CitronDenver$8K
- Sarah BullDenver$4K
- Leslie GamacheDenver$4K
- Claudia PanzerDenver$3K
- Sheila MaierDenver$2K
- Karin HickeyDenver$2K
- Gregory LundDenver$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.